DVAX - Dynavax Technologies Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.01
-0.02 (-0.33%)
As of 9:34AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close6.03
Open6.27
Bid6.00 x 4000
Ask6.31 x 1000
Day's Range6.00 - 6.03
52 Week Range2.60 - 12.05
Volume34,173
Avg. Volume1,251,185
Market Cap504.029M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-2.38
Earnings DateFeb 23, 2020 - Feb 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
  • Benzinga

    The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...

  • GlobeNewswire

    Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors

    Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer has been appointed Chief Executive Officer and to the Board of Directors. David Novack has been appointed President and Chief Operating Officer, reporting to Mr. Spencer. “Through a rigorous, comprehensive search process, Ryan emerged as the right business leader to guide Dynavax, given his strong command of our business and proven ability to lead and drive commercial execution in a complex operating environment,” commented Arnold L. Oronsky, Ph.D., Chairman of the Board of Directors.

  • These Hedge Funds Snapped Up Dynavax Technologies Corporation (DVAX) Before Q4 Surge
    Insider Monkey

    These Hedge Funds Snapped Up Dynavax Technologies Corporation (DVAX) Before Q4 Surge

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • GlobeNewswire

    Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide

    Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Albertsons Companies, one of the largest food and drug retailers in the United States, have partnered to provide HEPLISAV-B at Albertsons Companies’ more than 1,700 pharmacies nationwide, with a special focus on people living with diabetes. Through this partnership, patients will have access to HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for adults that is completed in one month. HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

  • Is the Options Market Predicting a Spike in Dynavax (DVAX) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Dynavax (DVAX) Stock?

    Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.

  • GlobeNewswire

    Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed

    Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has filed a report on a cumulative analysis (comprising both required interim analyses)  of its post-marketing study of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] for review by the U.S. Food and Drug Administration (FDA). The study is assessing the rates of occurrence of acute myocardial infarction (AMI) in persons receiving HEPLISAV-B compared with Engerix-B.  The interim report assesses unadjudicated events of AMI. The event rates in this interim analysis were similar between the two treatment arms.

  • Thomson Reuters StreetEvents

    Edited Transcript of DVAX earnings conference call or presentation 6-Nov-19 9:30pm GMT

    Q3 2019 Dynavax Technologies Corp Earnings Call

  • GuruFocus.com

    Safety Could Determine Who Wins the Next-Generation HBV Vaccine Market

    The winner of the next-generation hepatitis B vaccine market could largely be determined by upcoming safety data between Sci-B-Vac and Heplisav-B Continue reading...

  • Hedge Funds Have Never Been Less Bullish On Dynavax Technologies Corporation (DVAX)
    Insider Monkey

    Hedge Funds Have Never Been Less Bullish On Dynavax Technologies Corporation (DVAX)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • GlobeNewswire

    Dynavax to Present at the Stifel 2019 Healthcare Conference

    EMERYVILLE, Calif., Nov. 07, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,.

  • Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates

    Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -22.50% and 5.07%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Dynavax Announces Third Quarter 2019 Financial Results

    Third quarter 2019 HEPLISAV-B® net product revenue of $10.2 millionRaising revenue expectation range to $34-$36 million for full year 2019Conference call to be held today at.

  • Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
    Zacks

    Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Dynavax to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6

    EMERYVILLE, Calif., Oct. 24, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines, will report third.

  • Imagine Owning Dynavax Technologies (NASDAQ:DVAX) And Trying To Stomach The 73% Share Price Drop
    Simply Wall St.

    Imagine Owning Dynavax Technologies (NASDAQ:DVAX) And Trying To Stomach The 73% Share Price Drop

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We...

  • 3 Biotech Stocks That Could Triple in 2020
    TipRanks

    3 Biotech Stocks That Could Triple in 2020

    2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is down more than six percentage points, against near 16% rise for the S&P 500.But not all biotechs are created equal -- and not all biotech stocks will remain as cheap as they are today. Utilizing the Stock Screener at TipRanks to seek out strong-buy-rated stocks with incredible profit potential, we've come up with a trio of small cap biotechs with a chance to triple their share price (or more) in the coming year. Let's take a closer look:Aurinia Pharmaceuticals (AUPH)Based out of Victoria, British Columbia, Aurinia Pharmaceuticals is a clinical-stage biotech developing a drug called voclosporin, which it hopes will prove useful in treating lupus nephritis (LN), an autoimmune disease affecting the kidneys, focal segmental glomerulosclerosis (another kidney disease) -- or if not those, then maybe dry eye syndrome.If that sounds to you like Aurinia hasn't quite decided "what it wants to be when it grows up" ... well, we kind of wonder about that, too. Still, the company has $131 million in the bank and minimal debt. With a cash burn rate of only $51 million, Aurinia has the better part of three years to figure itself out and get its drug to market to accomplish something.Just recently, Oppenheimer analyst Justin Kim initiated coverage of Aurinia stock with an outperform rating on the theory that voclosporin "could become the first therapeutic approved for treatment of LN." Kim thinks the drug has a 60% chance of proving successful for that purpose, and the stock could be worth $10 a share if that's the only indication the drug is approved for. If voclosporin proves effective in treating the other two diseases, the stock could be worth even more. (To watch Kim's track record, click here)"Considering the near-term readout of the pivotal Phase 3 LN study, we anticipate shares could re-rate following a positive primary outcome in 4Q19. In addition to an initial pipeline opportunity in FSGS and a maturing late-stage program in dry eye syndrome, we are positive on the stock’s setup into 2020," Kim opined.All in all, Wall Street likes the risk/reward factor at play here, as TipRanks showcases a strong buy consensus rooting for Aurinia's success. In fact, the consensus of analysts following Aurinia is that this stock could triple in value over the next 12 months, rising from $5 and approaching $17 per share. (See AUPH's price targets and analyst ratings on TipRanks)TherapeuticsMD (TXMD)TherapeuticsMD is a somewhat different story. On the one hand, it's a higher-price stock with nearly twice Aurinia's market capitalization, and a weaker balance sheet -- $183 million in cash, and $198 million in debt -- with a much higher burn rate of $152 million per annum. On the other hand, TherapeuticsMD has several products under development, including two formulations of topical progesterone cream.TherapeuticsMD even has products on the market, including estrogen insert "Imvexxy," for the treatment of menopause-related dyspareunia (sales of which are accelerating year over year), "Bijuva" for the treatment of menopause-related "hot flashes," and soon, "Annovera," a contraceptive insert.Cowen analyst Ken Cacciatore commented that Imvexxy sales were growing "in line with our expectations," that the company is "making progress" with Bijuva, and that it's "optimistic" about Annovera's launch early next year. On Imvexxy in particular, Cacciatore highlighted the 41% year over year growth in paid prescriptions written, and noted that patients using the drug are refilling their prescriptions at nearly twice the usual rate for products in this category.Despite the apparently weak balance sheet, Cacciatore believes"the company remains sufficiently capitalized to reach profitability" by the second half of 2021.Oppenheimer Jay Olson echoes Cacciatore's tone, noting, "We believe TXMD offers a unique portfolio of women's health products that currently remains undervalued with attractive market opportunities. Based on our hypothetical SOTP analysis, we value Imvexxy at $2/share, Bijuva at $5/share, and Annovera at $1/share."Street analysts agree, TherapeuticsMD stock could triple off of today's sub-$4 share price and approach $12 per share in the next 12 months. (See TXMD's price targets and analyst ratings on TipRanks)Dynavax Technologies (DVAX) Last but not least \-- well actually, it is least in terms of market capitalization at just $305 million -- we come to Dynavax Technologies, which sells the hepatitis B vaccine Heplisav-B, and has a phase 2 clinical trial candidate for cancer immunotherapy (DV281) and a phase 2a candidate for asthma treatment as well (AZD1419) -- along with a phase 1 clinical trial product for the treatment of non-small cell lung cancer (DV281).Like TherapeuticsMD , Dynavax is a company in perilous financial state, with a cash-poor balance sheet ($140 million cash, $213 million debt) and a rapid cash burn rate -- $158 million per annum. Regardless, Cowen analyst Phil Nadeau has high hopes for this one, noting that Heplisav "has been shown to be more effective and more convenient than the other currently marketed HBV vaccines in a number of Phase III trials," which suggests Dynavax may be safe from competition in this space for some time.Indeed, already Nadeau says Heplisav is gaining market share, and predicts the drug could capture as much as $365 million of the $500 million-plus market for hepatitis B vaccines by 2024 -- a better than 70% market share.As a result, Nadeau rates DVAX an Outperform with a $20 price target, which implies a whopping 440% upside from current levels. (To watch Nadeau's track record, click here)"With Heplisav's label favorable, we expect it to become the market-leading HBV vaccine over time. Our consultants think that the other monovalent HBV vaccines are good, but not ideal. Although quite safe and generally effective, our consultants think they have two shortfalls: First, they are not perfectly effective, particularly in “hyporesponders” – people over the age of 40 and people with a number of diseases – for whom they provide suboptimal protection. Second, the marketed HBV vaccines require 3 (or more) doses over six months, which reduces compliance and hence protection," Nadeau noted.Analysts following the stock believe Dynavax shares to be significantly undervalued at today's sub-$4 share price, and predict Dynavax could go to $16 next year. More than a mere triple -- this stock could quadruple in 2020. (See DVAX's price targets and analyst ratings on TipRanks)

  • GlobeNewswire

    Dynavax to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim.

  • Thomson Reuters StreetEvents

    Edited Transcript of DVAX earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Dynavax Technologies Corp Earnings Call

  • Here's How to Find Top-Ranked Stocks Under $10 to Buy
    Zacks

    Here's How to Find Top-Ranked Stocks Under $10 to Buy

    Here's How to Find Top-Ranked Stocks Under $10 to Buy

  • We Think Dynavax Technologies (NASDAQ:DVAX) Has A Fair Chunk Of Debt
    Simply Wall St.

    We Think Dynavax Technologies (NASDAQ:DVAX) Has A Fair Chunk Of Debt

    Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

  • Dynavax Technologies Corporation (DVAX) Shares March Higher, Can It Continue?
    Zacks

    Dynavax Technologies Corporation (DVAX) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Dynavax Technologies Corporation (DVAX).

  • GlobeNewswire

    Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors

    Bain Capital Life Sciences Managing Director brings extensive capital markets and diverse life sciences industry experience EMERYVILLE, Calif., Aug. 12, 2019 -- Dynavax.

  • Dynavax Technologies Corp (DVAX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Dynavax Technologies Corp (DVAX) Q2 2019 Earnings Call Transcript

    DVAX earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock

    EMERYVILLE, Calif., Aug. 08, 2019 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and.

  • Dynavax Technologies (DVAX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Dynavax Technologies (DVAX) Reports Q2 Loss, Tops Revenue Estimates

    Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -4.76% and 4.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?